News
More than half of US women feel anxious about reproductive care access- survey
More than half of women in the US feel anxious about access to reproductive healthcare, new figures have shown.
The Reproductive Rights Watch survey, conducted by the telehealth company Nurx, shed light on women’s sentiments towards reproductive rights in the US ahead of the 2024 election, showing significant anxiety, changed behaviours and economic implications among women.
Nurx surveyed more than 1,000 women to understand how much agency they feel over their ability to make choices regarding their health and how current national and state reproductive policies influence their decisions.
Among the findings, 54 per cent of women surveyed are anxious about their reproductive and sexual freedoms given the political environment, and 49 per cent of women feel anxiety about accessing in-person care for their reproductive and sexual health.
The survey found that an astounding 71 per cent of women have made at least one health-related behaviour change, including delaying preventative care visits (25 per cent) or seeking emergency contraception (20 per cent) due to the political climate. Other behaviour changes pose a potential economic impact, including considering changing where they work or live (31 per cent).
“This data is a powerful reminder of why reproductive rights matter,” said Caroline Hofmann, chief business officer at Nurx.
“Women are navigating a fraught healthcare environment — causing confusion and unease as they navigate an onslaught of misinformation and constant change.
“Nurx has always been committed to providing easy and trusted access to the high-quality care, clinical expertise, and education women deserve — and we are dedicated to doubling down on that commitment now, when it matters most.”
The survey found that women are experiencing longer than usual wait times for in-person reproductive and sexual health providers. More than one-third of women surveyed are now using telehealth due to the political environment.
Dr Navya Mysore, medical director for women’s health at Nurx, said: “Women are feeling distressed, anxious about the political climate, their ability to access critical in-person care, and their reproductive care needs.
“Their concerns are impacting important, everyday decisions they are making about their health.
“As part of the Nurx clinical team, our goal is to educate and provide patients with evidence-based medical information so they can make the best choices for their individual healthcare needs.”
A concierge doctor in Palo Alto provides a tailored healthcare experience that addresses specific needs and concerns of expectant mothers. This approach ensures more personalized and attentive care.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Hormonal health2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






